This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Biopsy- and biology-driven optimization of targete...
Clinical trial

Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation-positive melanoma

Read time: 1 mins
Last updated:17th Apr 2013
To broaden the understanding of molecular characterization of the melanoma in correlation to the clinical response (defined as partial response according to RECIST) at week 8 of targeted therapy (GSK2118436 (BRAFi) versus GSK2118436 (BRAFi) and GSK1120212 (MEKi)) for subjects with advanced/metastatic BRAF V600E/K mutation-positive cutaneous melanoma
Category Value
Study start date 2013-04-17

View full details